Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Accounts Payables (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Accounts Payables for 7 consecutive years, with $480000.0 as the latest value for Q3 2025.

  • For Q3 2025, Accounts Payables rose 57.89% year-over-year to $480000.0; the TTM value through Sep 2025 reached $480000.0, up 57.89%, while the annual FY2024 figure was $390000.0, 67.45% down from the prior year.
  • Accounts Payables hit $480000.0 in Q3 2025 for Cyclerion Therapeutics, up from $462000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.9 million in Q1 2023 and bottomed at $304000.0 in Q3 2024.
  • Average Accounts Payables over 5 years is $1.4 million, with a median of $1.1 million recorded in 2021.
  • Year-over-year, Accounts Payables surged 1755.93% in 2021 and then tumbled 81.12% in 2024.
  • Cyclerion Therapeutics' Accounts Payables stood at $1.8 million in 2021, then soared by 62.47% to $3.0 million in 2022, then crashed by 59.66% to $1.2 million in 2023, then plummeted by 67.45% to $390000.0 in 2024, then grew by 23.08% to $480000.0 in 2025.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $480000.0, $462000.0, and $483000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.